Prime Medicine, Inc. (PRME) Stock Forecast & Price Target

Compare

837 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PRME Analyst Ratings

Moderate Buy

4 Buy

3 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Prime

Medicine, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PRME Stock 12 Month Forecast

Average Price Target

$6.06

▲(64.23% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Prime Medicine, Inc. in the last 3 months. The average price target is $6.06 with a high forecast of $9.00 and a low forecast of $4.25. The average price target represents a 64.23% change from the last price of $3.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.923076923076923,4.346153846153846,4.769230769230769,5.1923076923076925,5.615384615384615,6.038461538461538,6.461538461538462,6.884615384615385,7.3076923076923075,7.730769230769231,8.153846153846153,8.576923076923077,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.6969230769230768,3.893846153846154,4.090769230769231,4.287692307692308,4.484615384615385,4.681538461538461,4.878461538461538,5.075384615384615,5.272307692307692,5.469230769230769,5.666153846153845,5.863076923076923,{"y":6.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.5576923076923075,3.6153846153846154,3.673076923076923,3.730769230769231,3.7884615384615383,3.8461538461538463,3.9038461538461537,3.9615384615384617,4.019230769230769,4.076923076923077,4.134615384615385,4.1923076923076925,{"y":4.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$9.00

Average Price Target$6.06

Lowest Price Target$4.25

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Jubinville, PhD

LifeSci Capital

Buy

62.60%

Upside

Initiated

12/23/25

Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s DiseaseWe are iniang coverage on Prime Medicine (Nasdaq: PRME) under our an OUTPERFORM rang and price target of $6/share. Prime is a biotechnology company developing one-and-done gene eding therapies with a recently refocused pipeline centered around high-value indicaons with signiﬁcant unmet need, including Wilson’s disease (WD), alpha-1 antrypsin deﬁciency (AATD), and cysc ﬁbrosis (CF). All of these programs ulize prime eding to permanently correct the causave mutaons in each indicaon, providing a diﬀerenated approach to other CRISPR-based systems or more tradional AA V-mediated gene therapy by allowing for hotspot or mutaon-agnosc correcons to capture a larger paent pool with a theorecally improved safety proﬁle.

Tessa Romero

J.P. Morgan

Hold

―

Reiterated

11/18/25

Prime Medicine transferred with Neutral rating at JPMorganPrime Medicine transferred with Neutral rating at JPMorgan

Arthur He CFA

H.C. Wainwright

Hold

―

Reiterated

11/13/25

Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline

Samantha Semenkow

Citi

$5→$4.25

Hold

15.18%

Upside

Reiterated

11/11/25

Prime Medicine price target lowered to $4.25 from $5 at CitiPrime Medicine price target lowered to $4.25 from $5 at Citi

Soumit Roy

JonesTrading

Buy

35.50%

Upside

Reiterated

11/11/25

Prime Medicine's Promising Advances in Gene Editing Justify Buy Rating

Geulah Livshits

Chardan Capital

Buy

143.90%

Upside

Reiterated

11/09/25

RATING Buy PRICE TARGET $9.00 Updating our model for 3Q25 financials including updated dilution information for Prime's July offering brings our PT to $9.

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debjit Chattopadhyay

Guggenheim

$18→$5

Buy

35.50%

Upside

Reiterated

08/13/25

Guggenheim Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)

Terence Flynn

Morgan Stanley

Hold

―

Reiterated

08/11/25

PRME.O Prime Medicine Inc Equal-Weight; Price target initiated at 3.79.

Silvan Tuerkcan

Citizens JMP

Buy

62.60%

Upside

Reiterated

06/18/25

Citizens JMP Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

Maury Raycroft

Jefferies

$13→$9

Buy

143.90%

Upside

Reiterated

05/19/25

Prime Medicine (PRME) PT Lowered to $9 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Prime Medicine (NASDAQ: PRME) to $9.00 (from $13.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Jubinville, PhD

LifeSci Capital

Buy

62.60%

Upside

Initiated

12/23/25

Tessa Romero

J.P. Morgan

Hold

―

Reiterated

11/18/25

Prime Medicine transferred with Neutral rating at JPMorganPrime Medicine transferred with Neutral rating at JPMorgan

Arthur He CFA

H.C. Wainwright

Hold

―

Reiterated

11/13/25

Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline

Samantha Semenkow

Citi

$5→$4.25

Hold

15.18%

Upside

Reiterated

11/11/25

Prime Medicine price target lowered to $4.25 from $5 at CitiPrime Medicine price target lowered to $4.25 from $5 at Citi

Soumit Roy

JonesTrading

Buy

35.50%

Upside

Reiterated

11/11/25

Prime Medicine's Promising Advances in Gene Editing Justify Buy Rating

Geulah Livshits

Chardan Capital

Buy

143.90%

Upside

Reiterated

11/09/25

RATING Buy PRICE TARGET $9.00 Updating our model for 3Q25 financials including updated dilution information for Prime's July offering brings our PT to $9.

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debjit Chattopadhyay

Guggenheim

$18→$5

Buy

35.50%

Upside

Reiterated

08/13/25

Guggenheim Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)

Terence Flynn

Morgan Stanley

Hold

―

Reiterated

08/11/25

PRME.O Prime Medicine Inc Equal-Weight; Price target initiated at 3.79.

Silvan Tuerkcan

Citizens JMP

Buy

62.60%

Upside

Reiterated

06/18/25

Citizens JMP Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

Maury Raycroft

Jefferies

$13→$9

Buy

143.90%

Upside

Reiterated

05/19/25

Prime Medicine (PRME) PT Lowered to $9 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Prime Medicine (NASDAQ: PRME) to $9.00 (from $13.00) while maintaining a Buy rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prime Medicine, Inc.

1 Month

xxx

Success Rate

4/9 ratings generated profit

Average Return

+9.97%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +9.97% per trade.

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

+37.11%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +37.11% per trade.

1 Year

Soumit RoyJonesTrading

Success Rate

5/9 ratings generated profit

Average Return

+48.07%

reiterated a buy rating last month

Copying Soumit Roy's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +48.07% per trade.

2 Years

xxx

Success Rate

3/9 ratings generated profit

Average Return

+41.50%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +41.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRME Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PRME has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PRME average Analyst price target in the past 3 months is 6.06.

Each month's total comprises the sum of three months' worth of ratings.

PRME Financial Forecast

PRME Earnings Forecast

Next quarter’s earnings estimate for PRME is -$0.25 with a range of -$0.31 to -$0.19. The previous quarter’s EPS was -$0.32. PRME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.

PRME Sales Forecast

Next quarter’s sales forecast for PRME is $2.08M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $1.23M. PRME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.

PRME Stock Forecast FAQ

What is PRME’s average 12-month price target, according to analysts?

Based on analyst ratings, Prime Medicine, Inc.’s 12-month average price target is 6.06.

What is PRME’s upside potential, based on the analysts’ average price target?

Prime Medicine, Inc. has 64.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PRME a Buy, Sell or Hold?

Prime Medicine, Inc. has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.

What is Prime Medicine, Inc.’s price target?

The average price target for Prime Medicine, Inc. is 6.06. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $4.25. The average price target represents 64.23% Increase from the current price of $3.69.

What do analysts say about Prime Medicine, Inc.?

Prime Medicine, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PRME?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Prime Medicine, Inc. (PRME) Stock Forecast & Price Target

PRME Analyst Ratings

PRME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Prime Medicine, Inc.

PRME Analyst Recommendation Trends

PRME Financial Forecast

PRME Earnings Forecast

PRME Sales Forecast

PRME Stock Forecast FAQ

Detailed List of Analyst Forecasts